The pharmaceutical company Novo Nordisk and the telehealth platform Hims & Hers ended their legal dispute by concluding a partnership agreement.[1][2] Novo Nordisk sued Hims & Hers for patent infringement over offering a low-cost generic of its weight loss drugs Ozempic and Wegovy.[1] Hims & Hers previously offered compounded versions of semaglutide, the active ingredient in Novo's drugs, which Novo considered an infringement of its rights.[2] As part of the new collaboration, Hims & Hers will offer original Novo Nordisk medicines, including Wegova and Ozempica, in multiple dosages and forms.[4] Hims & Hers will continue to offer compounded semaglutide on a limited basis and will gradually transition customers to approved drugs when clinically appropriate.[4] Both companies plan to collaborate on other products in the future.[4] Shares of Hims & Hers rose nearly 40 percent after the deal was announced.[1]